Lake Forest, Illinois based Hospira acquired an active pharmaceutical ingredient (API) manufacturing facility and an associated research and development facility in Aurangabad from Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for $218 million.
“Hospira’s acquisition of the 665 employee Orchid API facility will support supply continuity of key beta-lactam antibiotic products, improve our cost position and pave the way for future API development,” said Dr. C. Bhaktavatsala Rao, president and managing director, Hospira India. In addition the purchase includes an associated Orchid R&D facility based in Chennai, India, that will be directed primarily to beta-lactam and other API development with approximately 110 scientific personnel.
